PDF(Pubmed)
Abstract：
UNASSIGNED: This analysis was aimed at providing evidence-based medicine basis for systematic evaluation of chondroitin combined with glucosamine in the treatment of knee osteoarthritis.
UNASSIGNED: The randomized controlled trials (RCTs) of chondroitin combined with glucosamine in the treatment of knee osteoarthritis (KOA) were searched in PubMed, EMBASE, ScienceDirect, Cochrane Library, China Knowledge Network Database (CNKI), China VIP Database, Wanfang Database, and China Biomedical Literature Database (CBM) online database. The retrieval time ranges from the database creation to the present. Two investigators gathered the information individually. The risk of bias was assessed using the criteria of the Cochrane back review group. RevMan5.4 statistical software analyzed the selected data.
UNASSIGNED: A total of 6 RCT articles were obtained. Overall, 764 samples were evaluated by meta-analysis. The clinical efficacy of chondroitin combined with glucosamine was significantly better than that of routine treatment by meta-analysis. The confidence interval of 95% was (4.86, 17.08) (Z = 6.89, P < 0.00001). The scores of joint pain, tenderness, swelling, and dysfunction in patients with knee osteoarthritis treated with chondroitin combined with glucosamine were significantly lower than those treated with routine treatment. There was no significant difference in the incidence of adverse reactions between chondroitin combined with glucosamine and single treatment of KOA. Due to the small number of documents included in the analysis, it is not suitable to make a funnel chart, but there may be some publication deviation in the analysis.
UNASSIGNED: Chondroitin combined with glucosamine is more effective than chondroitin or glucosamine alone in the treatment of KOA and deserves clinical promotion. However, this conclusion still needs to be supported by multicenter, high-quality, double-blind, large-sample randomized controlled clinical trials due to the limitations of the six trials included.
UNASSIGNED: The randomized controlled trials (RCTs) of chondroitin combined with glucosamine in the treatment of knee osteoarthritis (KOA) were searched in PubMed, EMBASE, ScienceDirect, Cochrane Library, China Knowledge Network Database (CNKI), China VIP Database, Wanfang Database, and China Biomedical Literature Database (CBM) online database. The retrieval time ranges from the database creation to the present. Two investigators gathered the information individually. The risk of bias was assessed using the criteria of the Cochrane back review group. RevMan5.4 statistical software analyzed the selected data.
UNASSIGNED: A total of 6 RCT articles were obtained. Overall, 764 samples were evaluated by meta-analysis. The clinical efficacy of chondroitin combined with glucosamine was significantly better than that of routine treatment by meta-analysis. The confidence interval of 95% was (4.86, 17.08) (Z = 6.89, P < 0.00001). The scores of joint pain, tenderness, swelling, and dysfunction in patients with knee osteoarthritis treated with chondroitin combined with glucosamine were significantly lower than those treated with routine treatment. There was no significant difference in the incidence of adverse reactions between chondroitin combined with glucosamine and single treatment of KOA. Due to the small number of documents included in the analysis, it is not suitable to make a funnel chart, but there may be some publication deviation in the analysis.
UNASSIGNED: Chondroitin combined with glucosamine is more effective than chondroitin or glucosamine alone in the treatment of KOA and deserves clinical promotion. However, this conclusion still needs to be supported by multicenter, high-quality, double-blind, large-sample randomized controlled clinical trials due to the limitations of the six trials included.
摘要：
■本分析旨在为系统评价软骨素联合氨基葡萄糖治疗膝骨关节炎提供循证医学依据。
■在PubMed中检索软骨素联合氨基葡萄糖治疗膝骨关节炎(KOA)的随机对照试验(RCT),EMBASE,ScienceDirect,科克伦图书馆,中国知网数据库(CNKI),中国VIP数据库,万方数据库,和中国生物医学文献数据库（CBM）在线数据库。检索时间的范围从数据库创建到现在。两名调查人员分别收集了信息。使用Cochrane回顾组的标准评估偏倚风险。RevMan5.4统计软件对所选数据进行分析。
■总共获得6篇RCT文章。总的来说,通过荟萃分析评估了764个样本。Meta分析显示,软骨素联合氨基葡萄糖治疗的临床疗效明显优于常规治疗。95%的置信区间为(4.86,17.08)(Z=6.89,P<0.00001)。关节疼痛的分数，压痛,肿胀,软骨素联合氨基葡萄糖治疗的膝骨关节炎患者的功能障碍明显低于常规治疗。软骨素联合氨基葡萄糖治疗与单纯KOA的不良反应发生率差异无统计学意义。由于分析中包含的文档数量很少，不适合做漏斗图，但分析中可能会有一些出版偏差。
■软骨素联合氨基葡萄糖治疗KOA疗效优于软骨素或氨基葡萄糖单独治疗，值得临床推广。然而,这一结论仍然需要多中心的支持，高品质，双盲,由于纳入的6项试验的局限性,大样本随机对照临床试验.
■在PubMed中检索软骨素联合氨基葡萄糖治疗膝骨关节炎(KOA)的随机对照试验(RCT),EMBASE,ScienceDirect,科克伦图书馆,中国知网数据库(CNKI),中国VIP数据库,万方数据库,和中国生物医学文献数据库（CBM）在线数据库。检索时间的范围从数据库创建到现在。两名调查人员分别收集了信息。使用Cochrane回顾组的标准评估偏倚风险。RevMan5.4统计软件对所选数据进行分析。
■总共获得6篇RCT文章。总的来说,通过荟萃分析评估了764个样本。Meta分析显示,软骨素联合氨基葡萄糖治疗的临床疗效明显优于常规治疗。95%的置信区间为(4.86,17.08)(Z=6.89,P<0.00001)。关节疼痛的分数，压痛,肿胀,软骨素联合氨基葡萄糖治疗的膝骨关节炎患者的功能障碍明显低于常规治疗。软骨素联合氨基葡萄糖治疗与单纯KOA的不良反应发生率差异无统计学意义。由于分析中包含的文档数量很少，不适合做漏斗图，但分析中可能会有一些出版偏差。
■软骨素联合氨基葡萄糖治疗KOA疗效优于软骨素或氨基葡萄糖单独治疗，值得临床推广。然而,这一结论仍然需要多中心的支持，高品质，双盲,由于纳入的6项试验的局限性,大样本随机对照临床试验.
